CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

Erythropoiesis-Stimulating Agents (ESAs) Coverage Criteria

Customize your policy alerts

Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage and medical necessity criteria for selected erythropoiesis-stimulating agents (epoetin alfa products, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta) for Blue Cross NC members; governs approval, required labs, indications, dosing limits, and duration of authorization.

Policy Summary

PayerBlue Cross Blue Shield - North Carolina

PolicyErythropoiesis-Stimulating Agents (ESAs) Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial clinical updates (criteria, pediatric labeling, step therapy removal)

Effective DateJun 16, 2021

Next Review DateMar 1, 2025

Key ActionObtain prior authorization with documentation of recent hemoglobin and iron studies and confirm supplemental iron when ferritin <100 mcg/L or TSAT <20%.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

Erythropoiesis-Stimulating Agents (ESAs) Coverage Criteria

Customize your policy alerts

Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - North Carolina

PolicyErythropoiesis-Stimulating Agents (ESAs) Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial clinical updates (criteria, pediatric labeling, step therapy removal)

Effective DateJun 16, 2021

Next Review DateMar 1, 2025

Key ActionObtain prior authorization with documentation of recent hemoglobin and iron studies and confirm supplemental iron when ferritin <100 mcg/L or TSAT <20%.

SourceLink

Coverage and Medical Necessity Criteria

Criteria for Approval of Restricted Product(s)

Covered when ALL of the following are met for the requested restricted product(s):

Core requirements: 1. The patient's transferrin saturation, serum ferritin, and hemoglobin have been evaluated in the last 4 weeks; AND 2. For patients with a serum ferritin of < 100 mcg/L or a serum transferrin saturation < 20%, supplemental iron therapy has been initiated;laboratory thresholds apply

These laboratory evaluations must be documented in the last 4 weeks.

Indication: Reduction of allogeneic transfusions: 3.a The patient is a candidate for elective, noncardiac, nonvascular surgery; AND 3.b The patient's hemoglobin is > 10 g/dL and ≤ 13 g/dL;Hb >10 and <=13 g/dL

Duration = 180 days

Indication: Anemia due to myelosuppressive chemotherapy: 4.a The patient has a non-myeloid malignancy; AND 4.b The patient's hemoglobin is < 10 g/dL in the last 4 weeks; AND 4.c The patient is currently on or has received chemotherapy in the last 6 months; AND 4.d Chemotherapy is not intended to be curative; AND 4.e The requested medication is NOT Mircera;Hb <10 g/dL

Duration = 180 days

Indication: Anemia associated with chronic kidney disease (CKD): 5.a The patient has been diagnosed with chronic kidney disease; AND either 5.b The patient is on dialysis with a hemoglobin of < 10 g/dL in the last 4 weeks OR 5.c The patient is not on dialysis with a hemoglobin of < 10 g/dL (in the last 4 weeks) and is steadily decreasing, indicating a high likelihood for RBC transfusion;Hb <10 g/dL

Duration = 365 days (or as specified)

Indication: Myelodysplastic syndrome: 6.a Diagnosis of myelodysplastic syndrome; AND either 6.b The patient's hemoglobin is < 12 g/dL when starting ESA therapy OR 6.c The patient's hemoglobin is ≤ 12 g/dL while receiving and stable on ESA therapy;Hb <=12 g/dL

Duration = 365 days

Indication: Zidovudine-related anemia (HIV): 7.a Diagnosis of HIV/AIDS; AND 7.b Being treated with zidovudine; AND either 7.c The patient's hemoglobin is < 12 g/dL when starting ESA therapy OR 7.d The patient's hemoglobin is ≤ 12 g/dL while receiving and stable on ESA therapy;Hb <=12 g/dL

Duration = 365 days

Clinical review approval for other supported diagnoses: 8. Prescriber has submitted documentation in support of the intended diagnosis which has been reviewed and approved by the Clinical Review pharmacist; AND either a. The patient's hemoglobin is < 12 g/dL when starting ESA therapy OR b. The patient's hemoglobin is ≤ 12 g/dL while receiving and stable on ESA therapy;Hb <=12 g/dL for approvals based on clinical review

Requested quantity must not exceed maximum units allowed for duration of approval.

The policy lists specific situations in which erythropoiesis‑stimulating agents (ESAs) are not indicated. ESAs are not indicated for use in patients with cancer receiving hormonal agents, biologic products, or radiotherapy unless they are also receiving concomitant myelosuppressive chemotherapy. They are also not indicated when chemotherapy is intended to be curative or when the anemia can be managed by transfusion. Additionally, ESAs are not indicated for patients scheduled for cardiac or vascular surgery, and they are not a substitute for immediate red blood cell (RBC) transfusion in patients who require immediate correction of anemia.

Use of ESAs as a substitute for RBC transfusions in patients who require immediate correction of anemia is not indicated and would be considered not medically necessary. The FDA‑labeled limitations reinforce that ESAs should not replace transfusion when rapid correction of hemoglobin is required.

Coding, Hemoglobin Thresholds, and Related Limits

FDA label HCPCS references (epoetin alfa)HCPCS

Q4081	HCPCS for epoetin alfa (Epogen) CKD dialysis only (document reference)
J0885	HCPCS for epoetin alfa (non-dialysis) (document reference)

FDA label HCPCS references (Retacrit)HCPCS

Q5106

HCPCS for epoetin alfa-epbx (Retacrit) non-dialysis (document reference)

FDA label HCPCS references (darbepoetin alfa)HCPCS

J0882	HCPCS for darbepoetin alfa (Aranesp) CKD dialysis only (document reference)
J0881	HCPCS for darbepoetin alfa (Aranesp) non-dialysis (document reference)

FDA label HCPCS references (Mircera)HCPCS

J0887	HCPCS for Mircera (PEG-epoetin beta) CKD dialysis only (document reference)
J0888	HCPCS for Mircera (PEG-epoetin beta) non-dialysis (document reference)

Hemoglobin thresholds — indication-specific

Surgery (reduction of allogeneic transfusions)Hemoglobin > 10 g/dL and ≤ 13 g/dL

Myelosuppressive chemotherapy-related anemiaHemoglobin < 10 g/dL (within last 4 weeks); must meet additional chemo-related criteria

Chronic kidney disease — on dialysisHemoglobin < 10 g/dL (within last 4 weeks)

Chronic kidney disease — not on dialysisHemoglobin < 10 g/dL (within last 4 weeks) and hemoglobin is steadily decreasing, indicating high likelihood for RBC transfusion

Myelodysplastic syndrome / Zidovudine-related anemiaHemoglobin < 12 g/dL when starting ESA, or Hemoglobin ≤ 12 g/dL while receiving and stable on ESA therapy

Prior Authorization, Documentation, and Denial Triggers

Prior Authorization

Prior authorization: labs, Hb thresholds, and prescriber review

Prior authorization is required for the requested ESA product. The prescriber must submit recent laboratory results (hemoglobin, transferrin saturation, and serum ferritin evaluated within the last 4 weeks) and demonstrate the indication-specific hemoglobin threshold is met for the requested use; the submission will be reviewed by a Clinical Review pharmacist. Applicable HCPCS/J-codes for prior authorization requests include J0885, Q4081, Q5106, J0882, J0881, J0887, and J0888 as listed in the policy coding sections.

Labs required: transferrin saturation, serum ferritin, hemoglobin within last 4 weeks.
Indication-specific hemoglobin thresholds must be met (see criteria: e.g., surgery >10 and ≤13 g/dL; chemotherapy <10 g/dL; CKD <10 g/dL; MDS/HIV thresholds ≤12 g/dL).
Prescriber submission is reviewed and approved by Clinical Review pharmacist before authorization.
Include applicable HCPCS/J-codes with the request (J0885, Q4081, Q5106, J0882, J0881, J0887, J0888).

Step Therapy

Key Definitions

Elective, noncardiac, nonvascular surgery — definition and scheduling

DefinitionElective, noncardiac, nonvascular surgery: patient is scheduled for elective surgery that is neither cardiac nor vascular (used as the surgical candidate definition for the indication to reduce allogeneic transfusions).

Timing / schedulingPatient must be scheduled for elective (planned) surgery — not for emergency procedures; used specifically to identify candidates for transfusion-reduction indication.

ExclusionsNot indicated for patients undergoing cardiac or vascular surgery or for those willing to donate autologous blood; not a substitute for immediate RBC transfusion.

Background and Clinical Context

Erythropoiesis‑stimulating agents (epoetin alfa products, darbepoetin alfa, and methoxy polyethylene glycol‑epoetin beta) are FDA‑labeled for the treatment of anemia due to chronic kidney disease (in patients on dialysis and not on dialysis), zidovudine‑related anemia in HIV, and for anemia associated with myelosuppressive chemotherapy (with the requirement that at initiation there are at least two additional months of planned chemotherapy). ESAs are also indicated to reduce allogeneic RBC transfusions for elective, noncardiac, nonvascular surgery. Limitations of use described in labeling include lack of demonstrated improvement in quality of life or fatigue, and specific settings where ESAs are not recommended (for example, certain cancer treatment contexts and as a substitute for immediate transfusion). Mircera has additional pediatric labeling for conversion from another ESA in patients aged 3 months to 17 years under specific conditions.